Monoclonal antibody which binds p40 subunit of interleukin-12.
| Inventor | Institute |
|---|---|
| Rosemonde Banks | University of Leeds |
| Cat. #: | 151022 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | IHC ; ELISA ; IHC ; RIA ; WB |
| Target: | Interleukin-12 (IL12) p40 subunit |
| Reactivity: | Human |
| Clone: | 1-1A4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Interleukin 12; Cytotoxic Lymphocyte Maturation Factor 4 KDa Subunit; NK Cell Stimulatory Factor Chain; Interleukin-12 Beta Chain; IL-12 Subunit P4; CLMF P4; NKSF2; Natural Killer Cell Stimulatory Factor; IL12; Subunit P4; Interleukin 12; CLMF2; IMD29; NKSF; P4 |
|---|---|
| Product description: | Monoclonal antibody which binds p40 subunit of interleukin-12. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Recombinant human IL-12 produced in Baculovirus. |
| Immunogen Uniprot ID: | P29459 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | IL-12 is a heterodimeric cytokine comprised of p35 and p40 subunits. IL-12 plays a central role in cell-mediated immunity, promoting the differentiation of CD4+ T cells to the Th1 subset and of CD8+ T cells into mature cytotoxic T lymphocytes (CTLs). Interleukin 12 (IL-12) is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells in response to antigenic stimulation. IL-12 is a potent stimulator of Natural Killer cells. IL-12 therapy has been suggested as a method of enhancing cytocidal anti-tumour immune responses. This antibody recognises the p40 subunit of human IL-12 and binds to both the free subunit and the p35/p40 heterodimer. It reacts with both stimulated and unstimulated monocytes in immunohistology. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Nagashima et al. 2008. Anticancer Res. 28(2B):1277-83. PMID: 18505066. Prognostic significance of the local expression of interleukin-12 in patients with advanced gastric cancer. Nakayama et al. 2004. Anticancer Res. 24(5C):3289-94. PMID: 15515423. Relationships between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer. Carter et al. 1997. Hybridoma. 16(4):363-9. PMID: 9309427. Production and characterization of monoclonal antibodies to human interleukin-12. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.